

**Manchester Health and Wellbeing Board
Report for Resolution**

Report to: Manchester Health and Wellbeing Board – 3 July 2013
Subject: Pharmacy Needs Assessment
Report of: David Regan, Director of Public Health

Summary

As part of its statutory role the Manchester Health and Wellbeing Board (HWB) is required to take responsibility for the current Manchester PCT Pharmaceutical Needs Assessment (PNA) and to take responsibility for the production of future PNAs. The PNA provides details of pharmacy services that would be required in a local area dependent on local health needs and future population trends.

Recommendations

The Board is asked to:

1. Agree the actions for the HWB as set out at 3.0
 2. Delegate the responsibility for these actions to the Director of Public Health
-

Board Priority Addressed:

All

Contact Officers:

Name: Barry Gillespie
Position: Consultant in Public Health
Telephone: 0161 234 3486
E-mail: b.gillespie@manchester.gov.uk

Background documents (available for public inspection):

Manchester Pharmacy Needs Assessment (2010)

1.0 Introduction

The Health and Social Care Act 2012 established Health and Wellbeing Boards (HWB). The Act also transferred responsibility to develop and update Pharmaceutical Needs Assessments (PNA) from Primary Care Trusts (PCTs) to HWBs. There is a requirement for the HWB to contribute to the publication of a revised PNA by 1 April 2015 or earlier, if possible. The previous PNA issued by the PCT will be adhered to until a revised version is published.

The PNA is a legal document which details pharmacy services which would be desirable and necessary in a locality based on the local health needs and population demographics. The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 set out the legislative basis for developing and updating PNAs and can be found at: <http://www.dh.gov.uk/health/2013/02/pharmaceutical-services-regulations>

PNAs will inform commissioning decisions by local authorities that relate to provision of public health services from community pharmacies and Clinical Commissioning Groups (CCGs). NHS England area teams will also use the PNA to inform whether a pharmacy application would be desirable for a particular location.

2.0 Background

The Greater Manchester Commissioning Support Unit (GMCSU) will, as agreed in the current service specification, lead the production of the new PNA for Manchester with City Council input to:

- form a Steering Group to oversee the development of the PNA (including Public Health, Commissioners and Local Engagement staff from the City Council)
- provide public health data and map services and health issues
- send out all communications and consultation documents, and to organise any public engagement events.

3.0 HWB Actions

The HWB is asked to:

1. Recognise the former PCT Pharmaceutical Needs Assessment and use it as a commissioning reference source until such a time as a revised PNA is produced.
2. Ensure that NHS England has access to-
 - a. the HWB's PNA (including any supplementary statement that it publishes, in accordance with regulation 6(3), that becomes part of that assessment);
 - b. any supplementary statement that the HWB publishes, in accordance with regulation 6(3), in relation to the PCT's PNA

c. any PCT PNA that it holds, which is sufficient to enable the NHS England to carry out its functions under these Regulations.

3. Ensure that, as necessary, other HWBs have access to any PCT PNA that it holds, which is sufficient to enable the other HWBs to carry out their functions under these Regulations

4. Note that the HWBB is required by the regulations to publish a revised assessment where it identifies changes to the need for pharmaceutical services “which are of a significant extent”. The only exception is where the HWB is satisfied that making a revised assessment would be a disproportionate response. The HWB will therefore need to put systems in place that allow them to:

a. Identify changes to the need for pharmaceutical services within their area

b. Assess whether the changes are significant and

c. Decide whether producing a new PNA is a disproportionate response.

5. Plan to publish a new PNA every 3rd year; unless a significant change to the need for pharmaceutical services are identified. (see 4.)

6. Ensure that when draft versions are submitted to the HWB that comments are received by the author in a timely fashion.

7. To publish a revised PNA by 31st March 2015